Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
Katie Couric Joins the Colorectal Cancer Alliance To ‘LEAD FROM BEHIND’
Katie Couric joins the Colorectal Cancer Alliance and Ryan Reynolds’ Maximum Effort to expand LEAD FROM BEHIND, a star-powered campaign breaking stigma and urging lifesaving colon cancer screening. Colon cancer is the preventable cancer.
Volunteer spotlight: Greg Schwem
In this Q&A, get to know Greg Schwem, a passionate and dedicated Colorectal Cancer Alliance volunteer from Illinois, and sign up to be a volunteer yourself!
Bottoms Up® Invitational Tops $4 Million in Four Years To Fuel Mission
The 2025 Bottoms Up® Invitational, hosted by Craig Melvin and Lindsay Czarniak, raised over $4.4 million in four years to support the Colorectal Cancer Alliance. The star-studded concert and golf event honors Melvin’s late brother and shines a spotlight on the rise of colorectal cancer in young adults.